Miromatrix Competitors

Delisted . USA . 
Stock . Miromatrix Medical
Miromatrix Medical competes with Anebulo Pharmaceuticals, Pmv Pharmaceuticals, Molecular Partners, Mineralys Therapeutics,, and AN2 Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Miromatrix Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Miromatrix Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Miromatrix Medical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

Miromatrix Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Miromatrix Medical and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Miromatrix and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Miromatrix Medical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PEPG
+ 0.85
ANTX
ANTX
+ 0.8
MLYS
PHVS
+ 0.68
PMVP
PEPG
+ 0.66
PMVP
PEPG
+ 0.66
MLYS
PHVS
+ 0.54
ANEB
  
High negative correlations   
PHVS
- 0.61
BNOX
BNOX
- 0.49
PMVP
BNOX
- 0.44
ANEB
MOLN
- 0.42
BNOX
PEPG
- 0.27
BNOX
NGENF
- 0.2
PEPG

Risk-Adjusted Indicators

There is a big difference between Miromatrix Stock performing well and Miromatrix Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Miromatrix Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ANEB  4.81  0.39  0.07  0.26  5.19 
(6.14)
 9.77 
(10.43)
 40.87 
PMVP  1.80 (0.20) 0.00 (0.32) 0.00 
 0.00 
 4.41 
(3.31)
 16.42 
ZIVO  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
BNOX  7.11  1.27  0.17 (14.83) 7.14 
(8.71)
 12.06 
(9.80)
 150.97 
MOLN  2.32 (0.10) 0.00 (0.20) 0.00 
 0.00 
 7.09 
(5.85)
 17.19 
MLYS  4.19  0.06  0.10 (0.17) 4.55 
(4.83)
 10.04 
(8.23)
 50.53 
ANTX  2.55  0.09  0.05  0.00  2.66 
(3.12)
 5.56 
(4.39)
 17.09 
PHVS  2.32 (0.19) 0.00  2.27  0.00 
 0.00 
 5.62 
(3.84)
 14.29 
PEPG  8.17 (0.13) 0.00 (0.18) 0.00 
 0.00 
 19.62 
(13.91)
 92.48 
NGENF  2.42 (0.06) 0.00  0.05  0.00 
 0.00 
 5.56 
(4.90)
 32.23 
All Fundamental Data

Miromatrix Medical Competitive Analysis

The better you understand Miromatrix Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Miromatrix Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Miromatrix Medical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ANEB PMVP BNOX MOLN MLYS ANTX PHVS PEPG NGENF ACRV
 19.58 
 1.71 
Anebulo
 1.61 
 1.26 
Pmv
 1.41 
 4.88 
Bionomics
 1.37 
 4.33 
Molecular
 5.56 
 14.25 
Mineralys
 0.71 
 1.40 
AN2
 1.42 
 16.67 
Pharvaris
 6.67 
 2.40 
PepGen
 1.59 
 1.92 
NervGen
 7.30 
 5.44 
Acrivon
Market Volatility
(90 Days Market Risk)
Dangerous
Unstable
Extremely Dangerous
Slightly risky
Somewhat reliable
Very risky
Not too volatile
Dangerous
Dangerous
Slightly risky
Market Performance
(90 Days Performance)
OK
Very Weak
OK
Very Weak
Modest
Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Dangerous
Low
Low
Quite High
Average
Very High
Quite High
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Strong Buy
Not Available
Strong Buy
Strong Buy
Hold
Strong Buy
Strong Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Hold
Strong Hold
Not Rated
Hold
Strong Sell
Strong Hold
Hold
Buy
Strong Sell
Strong Hold
Current Ratio
30.4
24.76
12.46
14.37
N/A
28.17
12.85
11.01
4.25
N/A
Net Asset
4.07 M
191.29 M
27.65 M
158.53 M
205.9 M
138.74 M
398.69 M
150.88 M
17.9 M
138.26 M
EBITDA
(8.05 M)
(85.45 M)
(9.84 M)
(51.65 M)
(192.4 M)
4.9 M
(96.85 M)
(96.23 M)
(11.33 M)
(59.85 M)
Operating Margin
N/A
N/A
89.1
-12.32
N/A
N/A
N/A
N/A
N/A
N/A
Current Valuation
43.75 M
(103.87 M)
14.16 B
(10.07 M)
649.59 M
(54.91 M)
584.15 M
(20.78 M)
48.78 M
(17.48 M)
Price To Book
3.93
0.37
829.81
1.01
4.43
0.46
2.83
0.68
5.13
0.84
Retained Earnings
(65.4 M)
(368.71 M)
(177.98 M)
(246.29 M)
(302.52 M)
(154.46 M)
(265.92 M)
(271.46 M)
N/A
(116.42 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
-1.01
1.45
-0.069
0.63
1.51
0.14
-3.01
0.98
1.7
0.86
Number Of Employees
2
47
8
158
51
41
92
81
4
58
Shares Outstanding
25.93 M
51.93 M
1.63 M
36.87 M
62.8 M
29.88 M
54.23 M
32.69 M
58.68 M
31.14 M
Cash Flow From Operations
(8.09 M)
(51.28 M)
(14.68 M)
(59.25 M)
(166.31 M)
(53.29 M)
(93.05 M)
(82.37 M)
(8.27 M)
(42.64 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
260.58 K
1.19 M
272.74 K
2.44 M
14.65 M
14.04 M
238.91 K
18.66 M
324.69 K
4.64 M
Return On Equity
-1.14
-0.29
-0.78
-0.34
-0.82
-0.54
-0.59
-0.79
-1.42
-0.46
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.66
-0.24
-0.4
-0.21
-0.53
-0.32
-0.33
-0.42
-0.67
-0.29
Number Of Shares Shorted
66.89 K
864.66 K
400.4 K
42.6 K
1.75 M
78.58 K
390.94 K
852.55 K
N/A
1.13 M
Book Value Per Share
0.15
3.39
1.32
3.84
3.84
2.94
5.47
3.64
0.31
6.33
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
4.07 M
191.29 M
27.65 M
158.53 M
205.9 M
138.74 M
398.69 M
150.88 M
17.9 M
138.26 M
Debt To Equity
N/A
0.045
0.012
0.02
N/A
N/A
0.001
N/A
0.032
N/A
Short Ratio
1.94
8.38
0.13
26.8
5.94
0.75
12.96
0.41
N/A
10.14
Target Price
6.0
6.0
9.58
10.74
36.71
2.67
36.94
12.2
N/A
20.88
Shares Owned By Institutions
28.18
81.35
16.22
9.72
84.0
46.3
89.4
99.62
N/A
74.93
Market Capitalization
42.79 M
64.4 M
4.95 M
161.88 M
894.88 M
42.13 M
917.08 M
73.56 M
87.43 M
157.86 M
Price To Earnings To Growth
N/A
-0.31
N/A
N/A
N/A
N/A
-0.12
N/A
N/A
N/A
Price To Earning
N/A
N/A
N/A
1.85
N/A
3.96
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
386.72
32.57
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
(8.2 M)
(58.71 M)
(15.49 M)
(54.04 M)
(177.81 M)
(64.73 M)
(99.83 M)
(89.98 M)
(12.73 M)
(60.39 M)
Earnings Per Share
-0.32
-1.14
-14.32
-1.8
-3.66
-1.99
-2.84
-2.85
-0.28
-2.66
Shares Owned By Insiders
64.22
2.48
33.91
N/A
2.0
22.5
9.49
0.38
25.27
22.06
Revenue
N/A
N/A
20 K
4.97 M
N/A
N/A
N/A
N/A
N/A
N/A
Working Capital
3.25 M
161.29 M
9.36 M
143.5 M
190.71 M
96.46 M
383.25 M
107.06 M
N/A
116.39 M
Cash And Equivalents
14.55 M
277.43 M
33.56 M
267.13 M
N/A
113.39 M
201.38 M
218.82 M
11.65 M
N/A
Cash Per Share
0.62
6.08
4.46
8.22
N/A
5.84
5.96
9.26
0.2
N/A
Gross Profit
N/A
N/A
(18.96 M)
(42.53 M)
N/A
N/A
N/A
N/A
N/A
N/A
Day Typical Price
1.59
1.26
4.98
4.34
14.06
1.41
16.71
2.33
1.93
5.36
Accumulation Distribution
9458.6
1931.41
0.0802
2.67
78225.2
1115.08
1616.27
19077.42
0.0205
885.41
Market Facilitation Index
0.0
N/A
0.42
0.0
0.0
0.0
0.0
0.0
0.04
0.0
Daily Balance Of Power
0.8
0.6667
(0.17)
(3.00)
0.8621
(0.25)
(0.25)
0.75
0.75
1.37037
Period Momentum Indicator
0.28
0.02
(0.07)
(0.06)
0.75
(0.01)
(0.24)
0.15
0.03
0.37
Rate Of Daily Change
1.2
1.02
0.99
0.99
1.06
0.99
0.99
1.07
1.02
1.07
Day Median Price
1.54
1.27
5.03
4.34
13.97
1.41
16.74
2.3
1.93
5.33
Price Action Indicator
0.31
0.005
(0.19)
(0.04)
0.66
(0.01)
(0.18)
0.17
0.005
0.3
Coefficient Of Variation
2830.24
(727.52)
1275.72
(914.03)
1912.26
33482.11
(1,746)
(2,559)
(99,976)
(2,687)
Mean Deviation
4.81
1.8
7.11
2.32
4.19
2.55
2.32
8.17
2.42
4.11
Jensen Alpha
0.3924
(0.20)
1.27
(0.10)
0.0576
0.089
(0.19)
(0.13)
(0.06)
(0.02)
Total Risk Alpha
1.51
0.0679
4.05
0.1888
1.55
0.5532
0.3255
1.83
0.7277
0.728
Sortino Ratio
0.0695
N/A
0.1745
N/A
0.1031
0.0498
N/A
N/A
N/A
N/A
Downside Variance
32.3
N/A
66.41
N/A
23.64
8.14
N/A
N/A
N/A
N/A
Standard Deviation
7.44
2.51
16.45
3.36
7.06
3.28
3.02
14.22
4.4
5.62
Kurtosis
5.85
3.44
40.2
1.3
18.51
1.28
0.2348
11.47
21.72
1.64
Potential Upside
9.77
4.41
12.06
7.09
10.04
5.56
5.62
19.62
5.56
10.17
Treynor Ratio
0.258
(0.32)
(14.83)
(0.20)
(0.17)
(0.0003)
2.27
(0.18)
0.0498
(0.15)
Maximum Drawdown
40.87
16.42
150.97
17.19
50.53
17.09
14.29
92.48
32.23
30.57
Variance
55.37
6.29
270.6
11.32
49.84
10.78
9.1
202.09
19.39
31.59
Market Risk Adjusted Performance
0.268
(0.31)
(14.82)
(0.19)
(0.16)
0.0097
2.28
(0.17)
0.0598
(0.14)
Risk Adjusted Performance
0.0387
(0.11)
0.0757
(0.08)
0.0529
0.01
(0.04)
(0.02)
0.0072
(0.02)
Skewness
1.88
(0.27)
5.56
0.3187
3.17
0.8994
0.5499
2.87
3.6
0.7366
Semi Deviation
5.19
N/A
7.14
N/A
4.55
2.66
N/A
N/A
N/A
N/A
Information Ratio
0.0531
(0.08)
0.0864
(0.07)
0.071
0.0433
(0.01)
(0.03)
0.029
(0.01)
Value At Risk
(10.43)
(3.31)
(9.80)
(5.85)
(8.23)
(4.39)
(3.84)
(13.91)
(4.90)
(8.24)
Expected Short fall
(6.14)
N/A
(8.71)
N/A
(4.83)
(3.12)
N/A
N/A
N/A
N/A
Downside Deviation
5.68
N/A
8.15
N/A
4.86
2.85
N/A
N/A
N/A
N/A
Semi Variance
26.93
N/A
50.98
N/A
20.72
7.06
N/A
N/A
N/A
N/A

Miromatrix Medical Competition Performance Charts

Five steps to successful analysis of Miromatrix Medical Competition

Miromatrix Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Miromatrix Medical in relation to its competition. Miromatrix Medical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Miromatrix Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Miromatrix Medical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Miromatrix Medical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Miromatrix Medical position

In addition to having Miromatrix Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Diversified Assets Thematic Idea Now

Diversified Assets
Diversified Assets Theme
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Miromatrix Stock

If you are still planning to invest in Miromatrix Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Miromatrix Medical's history and understand the potential risks before investing.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY